Our results showed that restriction of the G2/M checkpoint by WEE1 inhibition resulted in disturbed proteostasis and UPR activation in ovarian cancer cells with TP53 mutations, which was mediated by the NF‐κB‐governed SASP. The gene discussed is TP53; the disease is ovarian carcinoma.